Application of reagents for detecting blood metabolites in the preparation of products for the diagnosis of colorectal cancer
AssigneeCancer Hospital, Chinese Academy of Medical Sciences
InventorsWei Cui, Xiaoying Lou, Feng Chen, Jia Li
Life of this patent
Estimating the term…
Abstract
An application of a reagent for detecting blood metabolites in the preparation of a product for the diagnosis of colorectal cancer is provided, which belongs to the technical field of disease diagnostic reagents. The blood metabolites include one or more of BN03, BP01, TLCA, or LCA. These blood metabolites can distinguish between healthy individuals and patients with colorectal lesions, serving as biomarkers for colorectal cancer diagnosis.
Claims5
Application of a reagent for detecting blood metabolites in the preparation of a product for distinguishing colorectal cancer from healthy subjects, wherein the blood metabolites are 9,12,13-TriHOME (BN03), myristoyl-L-carnitine (BP01), taurocholic acid (TLCA), and lithocholic acid (LCA);
- the colorectal cancer refers to colorectal dysplasia, stage I colorectal cancer, or stage II colorectal cancer.
A system for distinguishing colorectal cancer from healthy subjects, characterized by comprising:
- an analysis unit for obtaining results of biomarkers of a subject, wherein the biomarkers are BN03, BP01, TLCA, and LCA;
- an evaluation unit for assigning corresponding evaluation scores based on the obtained biomarker results to derive a total score;
- the total score y=(−8.24)+2.0456×BN03+0.0730×BP01+(−0.0078)×LCA+(−0.2206)×TLCA;
- an output unit for generating the subject's colorectal cancer diagnosis result based on the total score obtained from the evaluation unit;
- the colorectal cancer refers to colorectal dysplasia, stage I colorectal cancer, or stage II colorectal cancer.
Dependencies are inferred from the claim text.